Bronchial asthma
Conditions
Interventions
Group A:Chinese drugs for reinforcing shen and supplementing qi placebo+Bushen Fangchuan Pian placebo
Group B:Bushen Fangchuan Pian (5 tablets, tid, orally taken for 12 weeks) + Chinese drugs for reinforcing shen and supplementing qi placebo
Group C:Chinese drugs for reinforcing shen and supplementing qi (125ml, bid, orally taken for 12 weeks) +Bushen Fangchuan Pian (placebo)
Sponsors
Huashan Hospital Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18 to 70 years old, male or female; 2.Able and willing to provide signed informed consent; 3.Patients with partial controlled and totally controlled asthma(the number of ACT>=20); 4.Qi deficiency syndrome, shen qi deficiency syndrome and deficiency of Shenyang syndrome according to Traditional Chinese medical Differentiation; 5.Without Respiratory tract infection and Acute asthma attack for the past four weeks; 6. Subjects with acute excerbation of asthma every year over the past two years.
Exclusion criteria
Exclusion criteria: 1. Patients with acute asthma attack in screening Phase; 2. Participated in clinical trials of other drugs for the past three months; 3. Patients who have previous cancer treatments; 4. Uncontrolled heart failure/infection or renal failure; 5. Previous diagnosis of COPD or other pulmonary diseases; 6. Hyperactivity of fire due to yin deficiency syndrome according to Traditional Chinese medical Differentiation; 7. Pregnant or planning pregnancy, breast-feeding women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time interval from the study beginning to the first acute exacerbation of asthma;The frequency of asthma; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood eosinophil counts;Lung function;Asthma Quality of Life Questionnair;ACT test; | — |
Countries
China
Contacts
Public ContactJingcheng Dong
Outcome results
None listed